Compare ImmunityBio Inc. Common Stock (IBRX) vs JD.Com Inc (JD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ImmunityBio Inc. Common Stock vs JD.Com Inc — how do they compare? ImmunityBio Inc. Common Stock trades at $10.49 (market cap $10.51B), while JD.Com Inc trades at $27.14 (market cap $36.62B). The key difference: JD.Com Inc is far larger — about 3.5× ImmunityBio Inc. Common Stock's market cap, and JD.Com Inc pays a 3.72% dividend while ImmunityBio Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold ImmunityBio Inc. Common Stock for 0 Days and JD.Com Inc for 85 Days on average.
| IBRX | JD | |
|---|---|---|
Market Cap | $10.51B | $36.62B |
Volume | 10,445,785 | 6,571,477 |
Sector | Health | Consumer Cyclical |
52-Week High | $11.55 | $34.53 |
52-Week Low | $1.98 | $25.19 |
Typical Hold Time | 0 Days | 85 Days |
Enterprise Value | $10.97B | $19.26B |
Dividend Yield | — | 3.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
JD.com stock trades at $27.03, up 2.0% today, with a bullish technical signal and strong analyst consensus. The company reported revenue of $1.31 trillion in 2025, though net income declined to $19.63 billion. Recent news highlights potential EU approval for its $2.5 billion Ceconomy acquisition, a key strategic move.
The outlook is positive given deep valuation discounts (P/E 17.9, P/S 0.2) and robust cash flow, but risks include revenue pressure and regulatory scrutiny. Analyst price targets average $35.86, implying significant upside from current levels if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ImmunityBio Inc. Common Stock
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →
